AAP
ZYNE

Arax Advisory Partners’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Arax Advisory Partners’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,648
Closed -$5K – 1362
2022
Q3 		$5K Hold
6,648
– – ﹤0.01% 832
2022
Q2 		$8K Buy
6,648
+1,648
+33% +$2.1K ﹤0.01% 694
2022
Q1 		$10K Buy
5,000
+2,500
+100% +$5.94K ﹤0.01% 663
2021
Q4 		$7K Hold
2,500
– – ﹤0.01% 724
2021
Q3 		$11K Buy
+2,500
New +$11.2K ﹤0.01% 636

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return